86 related articles for article (PubMed ID: 32321673)
1. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer.
Yu EY; Hancock ML; Aronson W; Flaig T; Belkoff L; Tutrone R; Taylor R; Hardigan PC; Getzenberg RH
Clin Genitourin Cancer; 2020 Dec; 18(6):436-443. PubMed ID: 32321673
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
3. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.
Coss CC; Jones A; Parke DN; Narayanan R; Barrett CM; Kearbey JD; Veverka KA; Miller DD; Morton RA; Steiner MS; Dalton JT
Endocrinology; 2012 Mar; 153(3):1070-81. PubMed ID: 22294742
[TBL] [Abstract][Full Text] [Related]
6. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
8. The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer.
Smith K; Galazi M; Openshaw MR; Wilson P; Sarker SJ; O'Brien N; Alifrangis C; Stebbing J; Shamash J
Clin Genitourin Cancer; 2020 Jun; 18(3):e217-e223. PubMed ID: 32171601
[TBL] [Abstract][Full Text] [Related]
9. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
10. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.
Ho TH; Nunez-Nateras R; Hou YX; Bryce AH; Northfelt DW; Dueck AC; Wong B; Stanton ML; Joseph RW; Castle EP
Clin Genitourin Cancer; 2017 Apr; 15(2):196-202.e1. PubMed ID: 27771244
[TBL] [Abstract][Full Text] [Related]
11. Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
Barata PC; Cooney M; Mendiratta P; Tyler A; Dreicer R; Garcia JA
Invest New Drugs; 2018 Dec; 36(6):1085-1092. PubMed ID: 30191523
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of ethinylestradiol for castration-resistant prostate cancer].
Hayashi T; Sekii Y; Katayama K; Kamoto A; Kakuta Y; Mori N; Itatani H; Yoshioka T
Nihon Hinyokika Gakkai Zasshi; 2014 Apr; 105(2):37-42. PubMed ID: 24908814
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Hirmand M; Smith MR
Lancet Oncol; 2014 May; 15(6):592-600. PubMed ID: 24739897
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
Chow H; Ghosh PM; deVere White R; Evans CP; Dall'Era MA; Yap SA; Li Y; Beckett LA; Lara PN; Pan CX
Cancer; 2016 Jun; 122(12):1897-904. PubMed ID: 27019001
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
19. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
Hu YH; Guo JC; Zhang M
Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
[TBL] [Abstract][Full Text] [Related]
20. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
Trump D
Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
